| Virksomhedsstatus | | NORMAL. |
| Sidst opdateret den 14.01.2019 og
angivet som gældende fra 14.01.2019 (2135
dage). |
Ingen historik.
| Branche | | Fremstilling af farmaceutiske præparater (212000). |
| Sidst opdateret den 14.01.2019 og
angivet som gældende fra 14.01.2019 (2135
dage). |
Ingen historik.
| Revisionfravalgt | | false. |
| Sidst opdateret den 09.06.2020 og
angivet som gældende fra 27.04.2020 (1666
dage). |
| Historik | Start | Stop |
|---|
| false | 27.04.2020 | |
| true | 14.01.2019 | 26.04.2020 |
| Kontaktoplysninger | | jdh@zerion.eu. |
| Sidst opdateret den 20.02.2024 og
angivet som gældende fra 20.02.2024 (272
dage). |
| Historik | Start | Stop |
|---|
| jdh@zerion.eu | 20.02.2024 | |
| ow@zerion.eu | 04.10.2022 | 19.02.2024 |
| Telefonnummer | | 40968018. |
| Sidst opdateret den 04.10.2022 og
angivet som gældende fra 04.10.2022 (776
dage). |
Ingen historik.
| Navne | | Zerion Pharma A/S. |
| Sidst opdateret den 25.12.2021 og
angivet som gældende fra 14.12.2021 (1070
dage). |
| Historik | Start | Stop |
|---|
| Zerion Pharma A/S | 14.12.2021 | |
| Zerion Pharma ApS | 15.02.2021 | 13.12.2021 |
| Zerion ApS | 14.01.2019 | 14.02.2021 |
| Binavne | | Zerion A/S. |
| Sidst opdateret den 25.12.2021 og
angivet som gældende fra 20.12.2021 (1064
dage). |
Ingen historik.
| Tegningsregel | | Selskabet tegnes af bestyrelsens formand eller næstformand i forening med en direktør eller af den samlede bestyrelse. |
| Sidst opdateret den 21.10.2019 og
angivet som gældende fra 21.10.2019 (1855
dage). |
| Fortolkning
(3 tegningsmuligheder)
| | formanden + 1 direktør |
| næstformanden + 1 direktør |
| bestyrelsen |
| Historik | Start | Stop |
|---|
| Selskabet tegnes af bestyrelsens formand eller næstformand i forening med en direktør eller af den samlede bestyrelse | 21.10.2019 | |
| Selskabet tegnes af en direktør | 14.01.2019 | 20.10.2019 |
Type af revisorbistand:Revisionspåtegning
Navn på revisionsvirksomhed:Deloitte Statsautoriseret Revisionspartnerselskab
Revisionsvirksomhedens CVR-nr.:33963556
Beskrivelse af revisor:State Authorised Public Accountant
Virksomhedens regnskabsklasse:Regnskabsklasse B
Grundlag for konklusion (revision):We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements
applicable in Denmark. Our responsibilities under those standards and requirements are further
described in the "Auditor’s responsibilities for the audit of the financial statements" section of this auditor’s
report. We are independent of the Entity in accordance with the International Ethics Standards Board for
Accountants’ International Code of Ethics for Professional Accountants (IESBA Code) and the additional ethical
requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with
these requirements and the IESBA Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis
for our opinion.
Konklusion (revision):We have audited the financial statements of Zerion Pharma A/S for the financial year 01. 01. 2023 - 31. 12. 2023, which comprise the income statement, balance sheet, statement of changes in equity, cash flow statement and notes, including a
summary of significant accounting policies. The financial statements are prepared in accordance with the
Danish Financial Statements Act.
In our opinion, the financial statements give a true and fair view of the Entity’s financial position at 31. 12. 2023 and of the results of its operations and cash flows for the financial year 01. 01. 2023 - 31. 12. 2023 in accordance
with the Danish Financial Statements Act.
Udtalelse om ledelsesberetningen (revision):Management is responsible for the management commentary.
Our opinion on the financial statements døs not cover the management commentary, and we do not express
any form of assurance conclusion thereon.
In connection with our audit of the financial statements, our responsibility is to read the management
commentary and, in doing so, consider whether the management commentary is materially inconsistent with
the financial statements or our knowledge obtained in the audit or otherwise appears to be materially
misstated.
Moreover, it is our responsibility to consider whether the management commentary provides the information
required by relevant law and regulations.
Based on the work we have performed, we conclude that the management commentary is in accordance with
the financial statements and has been prepared in accordance with the requirements of the Danish Financial
Statements Act. We did not identify any material misstatement of the management commentary.
Ingen nuværende registrering.
Ingen historik.
Ingen nuværende registrering.
Ingen historik.
| Hjemmeside | | www.zerion.eu. |
| Sidst opdateret den 04.10.2022 og
angivet som gældende fra 04.10.2022 (776
dage). |
Ingen historik.
LoginOpret gratis brugere-conomic integration